Lexicon Pharmaceuticals Shares Plunge On Proposed Public Offering

by Akanksha Bakshi, Benzinga Editor
July 27, 2022 5:42 PM | 1 min read |
  • Lexicon Pharmaceuticals, Inc. LXRX shares dropped 18% in the after-hours session on commencing an underwritten public offering to offer and sell shares of its common stock, par value of $0.001.
  • Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock.
  • The financial terms and quantum of the offering were not disclosed.
  • LXRX intends to use the net proceeds for funding pre-commercial and commercial launch activities for sotagliflozin in heart failure; funding continued development of sotagliflozin in heart failure, and LX9211 in neuropathic pain; and working capital and other general corporate purposes.
  • Price Action: LXRX shares are trading lower by 18.96% at $2.65 during the post-market session on Wednesday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsPenny StocksOfferingsSmall CapAfter-Hours CenterMoversTrading IdeasBiotechnologyBriefsHealth Carewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!